185 related articles for article (PubMed ID: 34964909)
1. Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC.
Lewis S; Cedillo MA; Lee KM; Bane O; Hectors S; Ma W; Wang P; Stocker D; Morris DV; Pinato D; Sung M; Marron T; Schwartz M; Taouli B
Abdom Radiol (NY); 2022 Mar; 47(3):969-980. PubMed ID: 34964909
[TBL] [Abstract][Full Text] [Related]
2. Utility of Early Posttreatment PET/CT Evaluation Using FDG or
Reizine E; Chalaye J; Mule S; Regnault H; Perrin C; Calderaro J; Laurent A; Amaddeo G; Kobeiter H; Tacher V; Itti E; Luciani A
AJR Am J Roentgenol; 2022 Feb; 218(2):359-369. PubMed ID: 34494448
[No Abstract] [Full Text] [Related]
3. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
4. Response Evaluation and Survival Prediction Following PD-1 Inhibitor in Patients With Advanced Hepatocellular Carcinoma: Comparison of the RECIST 1.1, iRECIST, and mRECIST Criteria.
Zhou M; Zhang C; Nie J; Sun Y; Xu Y; Wu F; Huang Y; Li S; Wang Y; Zhou Y; Zheng T
Front Oncol; 2021; 11():764189. PubMed ID: 34956885
[TBL] [Abstract][Full Text] [Related]
5. Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.
Doemel LA; Chapiro J; Laage Gaupp F; Savic LJ; Kucukkaya AS; Petukhova A; Tefera J; Zeevi T; Lin M; Schlachter T; Jaffe A; Strazzabosco M; Patel T; Stein SM
Eur Radiol; 2021 May; 31(5):2737-2746. PubMed ID: 33123796
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Radiological Tumor Response Based on iRECIST and RECIST 1.1 in Metastatic Clear-Cell Renal Cell Carcinoma Patients Treated with Programmed Cell Death-1 Inhibitor Therapy.
Zheng B; Shin JH; Li H; Chen Y; Guo Y; Wang M
Korean J Radiol; 2021 Mar; 22(3):366-375. PubMed ID: 33289356
[TBL] [Abstract][Full Text] [Related]
7. Local Tumor Control and Patient Outcome Using Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma: iRECIST as a Potential Substitute for Traditional Criteria.
Vernuccio F; Godfrey D; Meyer M; Williamson HV; Salama JK; Niedzwiecki D; Stephens SJ; Ronald J; Palta M; Marin D
AJR Am J Roentgenol; 2019 Dec; 213(6):1232-1239. PubMed ID: 31613663
[No Abstract] [Full Text] [Related]
8. mRECIST and EASL responses at early time point by contrast-enhanced dynamic MRI predict survival in patients with unresectable hepatocellular carcinoma (HCC) treated by doxorubicin drug-eluting beads transarterial chemoembolization (DEB TACE).
Prajapati HJ; Spivey JR; Hanish SI; El-Rayes BF; Kauh JS; Chen Z; Kim HS
Ann Oncol; 2013 Apr; 24(4):965-73. PubMed ID: 23223331
[TBL] [Abstract][Full Text] [Related]
9. mRECIST to predict survival in advanced hepatocellular carcinoma: Analysis of two randomised phase II trials comparing nintedanib vs sorafenib.
Meyer T; Palmer DH; Cheng AL; Hocke J; Loembé AB; Yen CJ
Liver Int; 2017 Jul; 37(7):1047-1055. PubMed ID: 28066978
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of HCC response to locoregional therapy: Validation of MRI-based response criteria versus explant pathology.
Gordic S; Corcuera-Solano I; Stueck A; Besa C; Argiriadi P; Guniganti P; King M; Kihira S; Babb J; Thung S; Taouli B
J Hepatol; 2017 Dec; 67(6):1213-1221. PubMed ID: 28823713
[TBL] [Abstract][Full Text] [Related]
11. RECIST 1.1 versus mRECIST for assessment of tumour response to molecular targeted therapies and disease outcomes in patients with hepatocellular carcinoma: a systematic review and meta-analysis.
Yu H; Bai Y; Xie X; Feng Y; Yang Y; Zhu Q
BMJ Open; 2022 Jun; 12(6):e052294. PubMed ID: 35649603
[TBL] [Abstract][Full Text] [Related]
12. CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus RECIST 1.1.
Gavanier M; Ayav A; Sellal C; Orry X; Claudon M; Bronowicki JP; Laurent V
Eur J Radiol; 2016 Jan; 85(1):103-112. PubMed ID: 26724654
[TBL] [Abstract][Full Text] [Related]
13. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study.
Kudo M; Finn RS; Qin S; Han KH; Ikeda K; Cheng AL; Vogel A; Tovoli F; Ueshima K; Aikata H; López CL; Pracht M; Meng Z; Daniele B; Park JW; Palmer D; Tamai T; Saito K; Dutcus CE; Lencioni R
J Hepatol; 2023 Jan; 78(1):133-141. PubMed ID: 36341767
[TBL] [Abstract][Full Text] [Related]
14. Response Assessment by Volumetric Iodine Uptake Measurement: Preliminary Experience in Patients with Intermediate-Advanced Hepatocellular Carcinoma Treated with Yttrium-90 Radioembolization.
Bargellini I; Crocetti L; Turini FM; Lorenzoni G; Boni G; Traino AC; Caramella D; Cioni R
Cardiovasc Intervent Radiol; 2018 Sep; 41(9):1373-1383. PubMed ID: 29654507
[TBL] [Abstract][Full Text] [Related]
15. Comparison of α-Fetoprotein Criteria and Modified Response Evaluation Criteria in Solid Tumors for the Prediction of Overall Survival of Patients with Hepatocellular Carcinoma after Transarterial Chemoembolization.
Zhang YQ; Jiang LJ; Wen J; Liu DM; Huang GH; Wang Y; Fan WZ; Li JP
J Vasc Interv Radiol; 2018 Dec; 29(12):1654-1661. PubMed ID: 30396842
[TBL] [Abstract][Full Text] [Related]
16. Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.
Arizumi T; Ueshima K; Takeda H; Osaki Y; Takita M; Inoue T; Kitai S; Yada N; Hagiwara S; Minami Y; Sakurai T; Nishida N; Kudo M
J Gastroenterol; 2014 Dec; 49(12):1578-87. PubMed ID: 24499826
[TBL] [Abstract][Full Text] [Related]
17. Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial.
Zhang W; Tong S; Hu B; Wan T; Tang H; Zhao F; Jiao T; Li J; Zhang Z; Cai J; Ye H; Wang Z; Chen S; Wang Y; Li X; Wang F; Cao J; Tian L; Zhao X; Chen M; Wang H; Cai S; Hu M; Bai Y; Lu S
J Immunother Cancer; 2023 Sep; 11(9):. PubMed ID: 37730273
[TBL] [Abstract][Full Text] [Related]
18. Comparison of RECIST and iRECIST criteria in patients with advanced lung cancer treated with nivolumab.
Singla R; Jajodia A; Agrawal RK; Rao A; Pasricha S; Batra U
J Cancer Res Ther; 2023; 19(5):1212-1218. PubMed ID: 37787285
[TBL] [Abstract][Full Text] [Related]
19. Reclassification of therapeutic response of unresectable hepatocellular carcinoma to anti-angiogenic therapy and immunotherapy using alpha RECIST.
Xu Y; Yang Y; Ouyang J; Zhou Y; Li L; Ye F; Yang H; Huang Z; Zhou A; Zhang W; Zhou J; Zhao X; Zhao H
Eur Radiol; 2024 Apr; 34(4):2244-2255. PubMed ID: 37740779
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
